Medicure Inc.
TSX : MPH

Medicure Inc.

January 27, 2010 09:04 ET

Medicure Announces TSX Delisting and Intention to Apply for Alternative Listing

WINNIPEG, MANITOBA--(Marketwire - Jan. 27, 2010) - Medicure Inc. ("Medicure" or the "Company") (TSX:MPH) announces that, following a review by the listings committee of the Toronto Stock Exchange (the "TSX"), the common shares of Medicure will be delisted from the TSX effective at the close of trading on February 26, 2010. While the Company will endeavor to meet the continued listing requirements of the TSX prior to the delisting date, the Company also intends to make application for listing of its common shares on the TSX Venture Exchange (the "TSX- V") or NEX to ensure continued and seamless trading liquidity for shareholders. The Company anticipates that a transfer of its stock exchange listing to the TSX-V or NEX would occur on or about the TSX delisting date.

Management of the Company notes that a transfer in its stock exchange listing to the TSX-V or NEX would provide greater operational efficiency and lower costs for the Company, while allowing shareholders continued liquidity on a recognized exchange.

As previously announced on June 25, 2009, the Company was subject to an ordinary course delisting review by the TSX as a result of its reliance on the "financial hardship" exemption under Section 604(e) of the TSX Company Manual. The decision of the TSX to delist Medicure's common shares is based on the Company's failure to meet continued listing requirements of the TSX.

The TSX, TSX-V and NEX exchanges are each owned and operated by the TMX Group Inc.

The Company is continuing its strategic review process as previously announced on January 13, 2010.

About Medicure Inc.

Medicure is a biopharmaceutical company focused on the research, development and commercialization of novel small molecules to treat cardiovascular and neurological disorders. The Company's primary business activity is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) in the United States for acute coronary syndromes.

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, and applicable Canadian securities laws. Specifically, this press release contains forward-looking statements regarding the intention of the Company to apply to list its common shares on the TSX Venture Exchange or NEX. Such forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise except as required by law. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Factors which may cause such differences include, among others, the Company's ability to meet all of the listing requirements of the TSX Venture Exchange and general economic conditions. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Such forward-looking statements are also based on a number of assumptions which may prove to be incorrect, including, among others, the ability of the Company to meet all of the listing requirements of the TSX Venture Exchange and general business and economic conditions. Additional risks and uncertainties relating to the Company and its business can be found in the "Risk Factors" section of its Form 20F for the year ended May 31, 2009.

Contact Information